491 related articles for article (PubMed ID: 23452553)
1. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Cone-Beam CT-Based Liver Perfusion Mapping to Predict Initial Response of Hepatocellular Carcinoma to Transarterial Chemoembolization.
Kim KA; Choi SY; Kim MU; Baek SY; Park SH; Yoo K; Kim TH; Kim HY
J Vasc Interv Radiol; 2019 Mar; 30(3):358-369. PubMed ID: 30819478
[TBL] [Abstract][Full Text] [Related]
4. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
[TBL] [Abstract][Full Text] [Related]
5. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
Lokken RP; Fidelman N; Kolli KP; Kerlan RK
J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
[TBL] [Abstract][Full Text] [Related]
7. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization.
Miyayama S; Yamashiro M; Hashimoto M; Hashimoto N; Ikuno M; Okumura K; Yoshida M; Matsui O
J Vasc Interv Radiol; 2013 Apr; 24(4):501-8. PubMed ID: 23452552
[TBL] [Abstract][Full Text] [Related]
8. Cone-Beam Computed Tomography-Based Spatial Prediction of Drug Dose After Transarterial Chemoembolization Using Radiopaque Drug-Eluting Beads in Woodchuck Hepatocellular Carcinoma.
Mikhail AS; Pritchard WF; Negussie AH; Inkiyad G; Long DJ; Mauda-Havakuk M; Wakim PG; van der Sterren W; Levy EB; Lewis AL; Karanian JW; Wood BJ
Invest Radiol; 2022 Aug; 57(8):495-501. PubMed ID: 35239613
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
10. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
12. The Role of Dual-Phase Cone-Beam CT in Predicting Short-Term Response after Transarterial Chemoembolization for Hepatocellular Carcinoma.
Müller K; Datta S; Gehrisch S; Ahmad M; Mohammed MA; Rosenberg J; Hwang GL; Louie JD; Sze DY; Kothary N
J Vasc Interv Radiol; 2017 Feb; 28(2):238-245. PubMed ID: 27914917
[TBL] [Abstract][Full Text] [Related]
13. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): preliminary data.
Uller W; Wiggermann P; Gössmann H; Klebl F; Salzberger B; Stroszczynski C; Jung EM
Clin Hemorheol Microcirc; 2011; 49(1-4):55-66. PubMed ID: 22214678
[TBL] [Abstract][Full Text] [Related]
15. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?
Loffroy R; Lin M; Yenokyan G; Rao PP; Bhagat N; Noordhoek N; Radaelli A; Blijd J; Liapi E; Geschwind JF
Radiology; 2013 Feb; 266(2):636-48. PubMed ID: 23143027
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
17. Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads.
Golowa YS; Cynamon J; Reinus JF; Kinkhabwala M; Abrams M; Jagust M; Chernyak V; Kaubisch A
J Vasc Interv Radiol; 2012 Aug; 23(8):1031-5. PubMed ID: 22739645
[TBL] [Abstract][Full Text] [Related]
18. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
[TBL] [Abstract][Full Text] [Related]
20. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]